Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Search
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Oncology
Oncology
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Immuno-Oncology
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Collaboration in Oncology
Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Ezabenlimab
Ezabenlimab, PD-1 antibody
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
CD137/FAP agonist
CD137/FAP agonist
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Brightline-1 trial launch in rare sarcoma
Mehdi Lahmar discusses “Brightline-1”, and our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
SIRPα antagonist
SIRPα antagonist
Expert Advice from Dr Clare Shaw
Consultant oncology dietitian Dr Clare Shaw shares her advice on some of the most common cancer nutrition misunderstandings.
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Targeting MDM2-p53 in cancer: The story of brigimadlin
Learn about the discovery of Brigimadlin, our MDM2-p53 antagonist, that is being developed for the treatment of dedifferentiated liposarcoma, a rare cancer
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform